Pfizer's (PFE) c.$12bn Zoetis, a Real Spinoff?

                Pfizer's (PFE) c.$12bn Zoetis, a Real Spinoff?

  PR Newswire

  NEW YORK and LONDON, January 31, 2013

NEW YORK and LONDON, January 31, 2013 /PRNewswire/ --

" This is an IPO, not a Spinoff… Well not yet! "   according to  Ryan
Mendy, COO of TSR ,   the  UK  based, leading global Spinoff and special
situations research firm.

 (Photo: )

TSR ' s specialist analyst team have been  looking at  Pfizer ' s (PFE)
various break-up potentials closely since 2010. Zoetis (ZTS), PFE ' s Animal
Health business, is one of 120+ break-ups on TSR's 2013 calendar,   but they
believe the best is to come for investors.

" Zoetis is due to be priced today, valued at c.$12bn " , comments Mendy .  "
Our research   sees a better investment angle on PFE if yo u want ZTS stock?
Large investors are apparently oversubscribed to the IPO. There ' s still over
two thirds [80%] of the company being held back by PFE management. Will they
be distributed tax-free? Much better returns are generated from Spinoffs  
than IPOs " .

And the TSR team have a real edge, they returned +23% in FY2012 to funds using
their research and they have a market leading history of both advising and
delivering institutional clients solid benchmark outperforming returns from
their fundamental analysis, weekly idea generation and recommendations on what
future Spinoffs and Distressed Equity Situations will perform best(?). You can
click here to see TSR's 5 year track record vs. major benchmarks.

PFE, valued at $197bn, are merely selling (raising money) for 20% of ZTS and
holding back the rest to see how it performs, thus with no current tax-free
distribution of the other 80% of stock back to current PFE shareholders, this
is a pure IPO , not a Spinoff .

It appears Compuware (CPWR) is aiming to carry out a similar process now, just
like Sunoco (SUN) did with its coke-making business SunCoke Energy (SXC) and
Dean Foods (DF) is planning with its consumer segment, WhiteWave (WWAV).

How to get more?

Click here to enquire regarding TSR's research of this and other Spinoff's in
the US, those in Europe and all other international markets, as well as their
upcoming deep value coverage calendar.

Investment sectors covered by The Spinoff Report®   & The Distressed Report™

Activism, Bankruptcy, Carve Outs, Deep Value, Catalysts, Demutualizations,
Directors Dealings, Distressed Securities, Liquidations, Merger Securities,
Mergers & Acquisitions, Post-Re-Orgs, Privatizations, Recapitalizations,
Recovery Situations, Equity Restructurings, Reverse Mergers, Reverse Morris
Trusts, Rights Offerings, Special Dividends, Spinoffs, Split-offs, Tender
Offers and Turnarounds.

Contact Ryan Mendy, COO The Spinoff Report® (TSR) +1-212-714-7046
Press spacebar to pause and continue. Press esc to stop.